AR119184A1 - Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas - Google Patents
Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismasInfo
- Publication number
- AR119184A1 AR119184A1 ARP200101717A ARP200101717A AR119184A1 AR 119184 A1 AR119184 A1 AR 119184A1 AR P200101717 A ARP200101717 A AR P200101717A AR P200101717 A ARP200101717 A AR P200101717A AR 119184 A1 AR119184 A1 AR 119184A1
- Authority
- AR
- Argentina
- Prior art keywords
- salt
- diffraction peaks
- fumarate
- crystalline form
- characteristic diffraction
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 9
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical group OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 6
- 238000002441 X-ray diffraction Methods 0.000 abstract 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 abstract 2
- -1 fumarate ion Chemical class 0.000 abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 2
- 239000012458 free base Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910542355 | 2019-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119184A1 true AR119184A1 (es) | 2021-12-01 |
Family
ID=74040655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101717A AR119184A1 (es) | 2019-06-21 | 2020-06-18 | Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220168302A1 (enExample) |
| EP (1) | EP3988546A4 (enExample) |
| JP (1) | JP2022538076A (enExample) |
| KR (1) | KR20220041090A (enExample) |
| CN (1) | CN115708409A (enExample) |
| AR (1) | AR119184A1 (enExample) |
| AU (1) | AU2020296048A1 (enExample) |
| BR (1) | BR112021025944A2 (enExample) |
| CA (1) | CA3144546A1 (enExample) |
| CL (1) | CL2021003438A1 (enExample) |
| CO (1) | CO2022000502A2 (enExample) |
| IL (1) | IL289231A (enExample) |
| MX (1) | MX2022000051A (enExample) |
| PH (1) | PH12021553151A1 (enExample) |
| WO (1) | WO2020253875A1 (enExample) |
| ZA (1) | ZA202200964B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022042738A1 (zh) * | 2020-08-31 | 2022-03-03 | 甘李药业股份有限公司 | 一种含cdk4/6抑制剂的药物组合物 |
| US20250332167A1 (en) * | 2021-05-17 | 2025-10-30 | Gan & Lee Pharmaceuticals Co., Ltd. | Pharmaceutical use of cdk 4/6 inhibitor |
| EP4696689A1 (en) * | 2023-04-04 | 2026-02-18 | Suzhou Kintor Pharmaceuticals, Inc. | Salt form and crystal form of chiral heterocyclic compound having hedgehog pathway antagonist activity |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK9742002A3 (en) * | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| CN106810536A (zh) * | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
-
2020
- 2020-06-18 AR ARP200101717A patent/AR119184A1/es not_active Application Discontinuation
- 2020-06-22 WO PCT/CN2020/097482 patent/WO2020253875A1/zh not_active Ceased
- 2020-06-22 EP EP20827805.1A patent/EP3988546A4/en not_active Withdrawn
- 2020-06-22 PH PH1/2021/553151A patent/PH12021553151A1/en unknown
- 2020-06-22 AU AU2020296048A patent/AU2020296048A1/en not_active Withdrawn
- 2020-06-22 KR KR1020227002390A patent/KR20220041090A/ko not_active Withdrawn
- 2020-06-22 CA CA3144546A patent/CA3144546A1/en active Pending
- 2020-06-22 JP JP2021576253A patent/JP2022538076A/ja active Pending
- 2020-06-22 US US17/596,721 patent/US20220168302A1/en not_active Abandoned
- 2020-06-22 MX MX2022000051A patent/MX2022000051A/es unknown
- 2020-06-22 BR BR112021025944A patent/BR112021025944A2/pt unknown
- 2020-06-22 CN CN202080045649.9A patent/CN115708409A/zh active Pending
-
2021
- 2021-12-21 IL IL289231A patent/IL289231A/en unknown
- 2021-12-21 CL CL2021003438A patent/CL2021003438A1/es unknown
-
2022
- 2022-01-20 ZA ZA2022/00964A patent/ZA202200964B/en unknown
- 2022-01-21 CO CONC2022/0000502A patent/CO2022000502A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3144546A1 (en) | 2020-12-24 |
| EP3988546A4 (en) | 2023-05-17 |
| EP3988546A1 (en) | 2022-04-27 |
| KR20220041090A (ko) | 2022-03-31 |
| MX2022000051A (es) | 2022-05-24 |
| CO2022000502A2 (es) | 2022-01-28 |
| US20220168302A1 (en) | 2022-06-02 |
| AU2020296048A1 (en) | 2022-02-10 |
| BR112021025944A2 (pt) | 2022-02-08 |
| CN115708409A (zh) | 2023-02-21 |
| PH12021553151A1 (en) | 2022-07-25 |
| WO2020253875A1 (zh) | 2020-12-24 |
| CL2021003438A1 (es) | 2022-09-30 |
| JP2022538076A (ja) | 2022-08-31 |
| IL289231A (en) | 2022-02-01 |
| ZA202200964B (en) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002825A (es) | Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia. | |
| AR087672A1 (es) | Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer | |
| BRPI0412347A (pt) | 2-aminofenil-4-fenilpiridinas como inibidores de quinase | |
| BR112014013974A2 (pt) | derivados de sulfonamida benzílicos como moduladores de rorc | |
| BR112022010377A2 (pt) | Novos tiromiméticos | |
| UY31069A1 (es) | Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones | |
| ECSP045221A (es) | Sales de valsartan | |
| MY137944A (en) | Specific glucocorticoid compounds having anti-inflammatory activity | |
| HUP0402454A2 (hu) | Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| GT200000216A (es) | Oxazolidinonas sustituidas y su uso. | |
| SV1999000047A (es) | Nuevas dihidropirimidinas fef. lea 32792-sv | |
| EP1845081A4 (en) | amide | |
| BRPI0414447A (pt) | derivado de quinazolina, composição farmacêutica, e, processo para a preparação de um derivado de quinazolina | |
| ES2322602T3 (es) | Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc. | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| IS2696B (is) | Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð | |
| NO20076695L (no) | Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser | |
| BRPI0409105A (pt) | análogos de quinobenzoxazina substituìdos | |
| EA200400208A1 (ru) | Фенилацетамидотиазольные производные, способ их получения и их использования в качестве противоопухолевых средств | |
| MX2016004963A (es) | Sal y formas cristalinas de inhibidores de quinasa tipo polo-4. | |
| BRPI0406704A (pt) | Antagonistas de 5ht~7~ e agonistas inversos | |
| UY29134A1 (es) | Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones | |
| EA200800439A1 (ru) | Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств | |
| AR056082A1 (es) | Formas cristalinas de clorhidrato de irinotecano (monoclorhidrato de 7-etil-10-[4-(1-piperidin)-1-piperidin]carboniloxicamptotecina trihidratado) y metodos de preparacion de las mismas | |
| MX2023010606A (es) | Formas de sales y sólidas de un inhibidor de cinasas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |